# A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

> **NCT04876092** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 45 (actual)

## Conditions studied

- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** JNJ-67856633
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT04876092
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-28
- **Primary completion:** 2025-02-13
- **Final completion:** 2025-02-13
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04876092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04876092, "A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04876092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*